SCHEMBL20436324

SCHEMBL20436324

Cc1cccc(NC(=O)ON2C(=O)CCC2=O)c1-c1c(C)cccc1N1CCOCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.47
▸ TSHR P16473 6/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ MCOLN3 Q8TDD5 1/20 0.47
▸ MEN1 O00255 4/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ NPSR1 Q6W5P4 3/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ LMNA P02545 5/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ NSD2 O96028 1/20 0.42
▸ PKM P14618 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20436323 0.89 MAPT (0.49) ALDH1A1TSHRSMN1; SMN2MEN1KMT2A
SCHEMBL20436319 0.77 POLB (0.46) ALDH1A1TSHRMEN1KMT2ANPSR1
SCHEMBL24200370 0.77 PARP14 (0.44) ALDH1A1MEN1KMT2ALMNAL3MBTL1
SCHEMBL20436314 0.77 ITGB1 (0.37) ALDH1A1MEN1KMT2ANPSR1LMNA
SCHEMBL4403976 0.76 ITGB1 (0.55) ALDH1A1SMN1; SMN2L3MBTL1TDP1KDM4E
SCHEMBL20436310 0.74 NLRP3 (0.36) ALDH1A1SMN1; SMN2NPSR1CYP1A2CYP2C19
SCHEMBL24200372 0.69 LMNA (0.34) ALDH1A1LMNAL3MBTL1KDM4EMAPT
SCHEMBL28032896 0.69 LMNA (0.65) ALDH1A1TSHRSMN1; SMN2MCOLN3MEN1
SCHEMBL20436325 0.68 L3MBTL1 (0.51) ALDH1A1TSHRSMN1; SMN2MCOLN3MEN1
SCHEMBL10030203 0.68 POLB (0.39) ALDH1A1SMN1; SMN2MEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11327060-B2 Method for analyzing enantiomer AJINOMOTO CO., INC. (JP) 2022-05-10 — — US disclosed
EP-3358346-B1 ENANTIOMER ANALYSIS METHOD AJINOMOTO KK (JP) 2022-01-19 — — EP disclosed
EP-3358346-A1 ENANTIOMER ANALYSIS METHOD Ajinomoto Co., Inc. (JP) 2018-08-08 — — EP disclosed
US-20180217113-A1 METHOD FOR ANALYZING ENANTIOMER AJINOMOTO CO., INC. (JP) 2018-08-02 — — US disclosed
US-20180217113-A1 METHOD FOR ANALYZING ENANTIOMER AJINOMOTO CO., INC. (JP) 2018-08-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11327060-B2 Method for analyzing enantiomer DCX, INF2, SRD5A2 ALDH1A1 834/4885TSHR 4304/4885SMN1; SMN2 3041/4885
US-20180217113-A1 METHOD FOR ANALYZING ENANTIOMER DCX, INF2, SRD5A2 ALDH1A1 834/4885TSHR 4304/4885SMN1; SMN2 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback